CARLSBAD, CALIFORNIA, Oct 30, 2013 (Marketwired via COMTEX) — Aurora Spine Corporation , a global minimally invasive (MIS) spinal implant company, is pleased to announce the first US surgical usage of the company’s AmnioPUR(TM) liquid allograft products in a lumbar spinal procedure. AmnioPUR was introduced in mid-October at EuroSpine congress in Liverpool, England and again at the North American Spine Society (NASS) in New Orleans, LA. AmnioPUR is a multipurpose, chorion free, cryopreserved allograft, AmnioPUR is derived from the amniotic membrane.
“Aurora Biologics, specifically our AmnioPUR product is another key step in bringing the best products to our worldwide distribution network. The clinical benefit of amnion is well documented, we just made it easier to use by providing AmnioPUR in a liquid form,” said Brent W. Johnston, CCO of Aurora Spine.
AmnioPUR(TM) provides an anti-microbial environment with anti-inflammatory characteristics and anti-adhesion/anti-fibrotic capabilities and provides a structural matrix for use in filling bone voids and soft tissue.
“The launch of AmnioPUR is a major milestone for Aurora Spine, as we now offer surgeons a comprehensive liquid allograft solution from a provider they trust,” said Trent J. Northcutt, President and CEO of Aurora Spine. “Surgeons know Aurora provides modern technologies for today’s patients ailing from spinal complications. Aurora is committed to the development, distribution and licensing arrangements of advanced biologics and tissue allografts, which make up one of the fastest growing segments in the global spine market.”
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.